Cover Image
市場調查報告書

菲律賓的醫藥品、醫療產業分析 (2015年第四季)

Philippines Pharmaceuticals and Healthcare Report Q1 2017

出版商 BMI Research 商品編碼 177615
出版日期 內容資訊 英文 98 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
菲律賓的醫藥品、醫療產業分析 (2015年第四季) Philippines Pharmaceuticals and Healthcare Report Q1 2017
出版日期: 2016年11月30日 內容資訊: 英文 98 Pages
簡介

菲律賓政府的2016年度預算,預計增額醫療部門預算。透過預算分配的增額,醫療保險體制整備,進行國內的醫療設備的更新。預期這樣的動向,促進國內醫療市場成長,更帶給各企業市場機會。但,高附加價值的價格上限,及知識產權的貧乏保護體制,成為跨國企業的潛在風險。菲律賓的醫藥品市場2014年達1450億5000萬比索 (32億2000萬美元),以及醫療市場達到5634億9000萬比索 (127億5000萬美元) 的規模。

本報告提供菲律賓的製藥、醫療產業結構和最新趨勢相關分析、今後10年的產業規模的動向估計、產業的課題 (風險) 和未來商機 (利潤) 相關評估、政府的政策與規定、宏觀經濟環境、主要企業簡介等資訊彙整,為您概述為以下內容。

BMI的見解

SWOT分析

  • 政治
  • 經濟
  • 經營風險

產業預測

  • 醫藥品市場預測
  • 醫療市場預測
  • 處方藥市場預測
  • 專利藥市場預測
  • 學名藥市場預測
  • 一般用醫藥品 (成藥) 市場預測
  • 醫藥品貿易的預測
  • BMI的預測方案相關主要風險

宏觀經濟預測

  • 經濟分析

產業的風險/利潤、等級

  • 亞洲:風險/利潤、等級
  • 菲律賓:風險/利潤、等級
    • 利潤
    • 風險

市場概況

產業的趨勢與發展

  • 流行病學
  • 醫療部門
  • 醫療保險
  • 醫療部門的資金籌措
  • 醫療觀光
  • 生物科技與研究
  • 傳統醫藥品
  • 臨床實驗

法規的發展

  • 知識產權的保護體制
  • 價格設定的體制
  • 醫療費償付的體制
  • 國際合作

競爭環境

  • 醫藥品產業
  • 國內的製藥產業
  • 醫藥品的流通、零售

企業簡介

  • GlaxoSmithKline Philippines
  • MediChem Pharmaceuticals
  • Merck & Co
  • Novartis
  • Pacific Pharmaceutical Generics
  • Pascual Laboratories
  • Pfizer
  • Sanofi
  • Unilab

人口結構的預測

詞彙表

分析方法

  • 醫藥品支出額的預測模式
  • 醫療費的預測模式
  • 分析方法的相關註記
  • 風險/利潤、等級技術
  • 等級概要
  • 指標的加權

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 1748-376X

BMI View: Despite high enrolment numbers with the Philippine Health Insurance Corporation (PhilHealth), further reforms to the Philippines's healthcare system will be necessary for the country's universal healthcare scheme to galvanise the pharmaceutical and healthcare sector. Factors such as a lack of human resources, poor patient accessibility to clinics and hospitals and limited insurance coverage will all hold back growth in the healthcare sector.

Headline Expenditure Projections

  • Pharmaceuticals: PHP150.44bn (USD3.33bn) in 2015, rising to PHP156.19bn (USD3.26bn) in 2016; +3.8% in local currency terms and -2.1% in US dollar terms. Forecast unchanged from last quarter.
  • Healthcare: PHP656.11bn (USD14.52bn) in 2015, rising to PHP722.32bn (USD15.06bn) in 2016; +10.1% in local currency terms and +3.8% in US dollar terms. Forecast unchanged from last quarter.

Risk/Reward Index

The Philippines is ranked in 14th place out of the 20 pharmaceutical markets assessed in Asia Pacific (scoring 45.0 out of 100), trailing the regional average in all subsectors. In Q117, Japan remains by far the most attractive market in the Asia Pacific region (scoring 80.6), followed by Australia (66.0).

Table of Contents

BMI Industry View

  • Table: Headline Pharmaceuticals & Healthcare Forecasts (Philippines 2014-2020)

SWOT

Industry Forecast

  • Pharmaceutical Market Forecast
    • Table: Pharmaceutical Sales, Historical Data And Forecasts (Philippines 2012-2020)
  • Healthcare Market Forecast
    • Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Philippines 2012-2020)
    • Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Philippines 2012-2020)
    • Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Philippines 2012-2020)
  • Prescription Drug Market Forecast
    • Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Philippines 2012-2020)
  • Patented Drug Market Forecast
    • Table: Patented Drug Market Indicators, Historical Data And Forecasts (Philippines 2012-2020)
  • Generic Drug Market Forecast
    • Table: Generic Drug Market Indicators, Historical Data And Forecasts (Philippines 2012-2020)
  • OTC Medicine Market Forecast
    • Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Philippines 2012-2020)
  • Pharmaceutical Trade Forecast
    • Table: Pharmaceutical Trade Data And Forecasts (Philippines 2014-2020)
    • Table: Pharmaceutical Trade Data And Forecasts Local Currency (Philippines 2014-2020)

Industry Risk/Reward Index

  • Asia Pacific Risk/Reward Index
  • Philippines Risk/Reward Index
    • Rewards
    • Risks

Regulatory Review

  • Intellectual Property Issues
  • Pricing Regime
  • Reimbursement Regime

Market Overview

  • Healthcare Sector
    • Table: Healthcare Resources (Philippines 2010-2015)
    • Table: Healthcare Personnel (Philippines 2010-2015)
    • Table: Healthcare Activity (Philippines 2010-2015)
  • Health Insurance
  • Clinical Trials
  • Epidemiology

Competitive Landscape

  • Research-Based Industry
    • Table: Multinational Market Activity
  • Generic Drugmakers
  • Pharmaceutical Distribution
  • Pharmaceutical Retail Sector
    • Table: Overview Of BnB, BNB and P100 Programme
    • Table: Cost Of Generic Drugs In Philippines (PHP)
    • Table: Number Of BnBs And BNBs In Selected Philippine Regions

Company Profile

  • GlaxoSmithKline Philippines
  • Novartis

Demographic Forecast

  • Table: Population Headline Indicators (Philippines 1990-2025)
  • Table: Key Population Ratios (Philippines 1990-2025)
  • Table: Urban/Rural Population & Life Expectancy (Philippines 1990-2025)
  • Table: Population By Age Group (Philippines 1990-2025)
  • Table: Population By Age Group % (Philippines 1990-2025)

Glossary

Methodology

  • Pharmaceutical Expenditure Forecast Model
  • Healthcare Expenditure Forecast Model
  • Notes On Methodology
  • Risk/Reward Index Methodology
  • Index Overview
    • Table: Pharmaceutical Risk/Reward Index Indicators
  • Indicator Weightings
Back to Top